Prot #CLDE225XUS20: Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 5 - LDE225 for patients with PTCH1 and SMO mutated tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date7/17/1412/31/17

Funding

  • United BioSource LLC (Prot #CLDE225XUS20)
  • Novartis Pharmaceuticals Corporation (Prot #CLDE225XUS20)